// App-Quantinova.ai

3211 : Open Label, Multicenter, Dose-Escalation/ Expansion Phase Ib Study to Evaluate Safety and Activity of BET Inhibitor RO6870810 (RO), Given As Monotherapy to Patients (pts) with Advanced Multiple Myeloma

Researchers

Presenter

  • Karthik Ramasamy

Principal Investigators

  • Ajay Nooka

  • Hang Quach

  • Myo Htut

  • Rakesh Popat

  • Michaela Liedtke

  • Sascha A Tuchman

  • Jacob P. Laubach

  • Cristina Gasparetto

  • Asher Chanan-Khan

  • Mark Hertzberg

  • Mark Demario

  • Eveline Nueesch

  • Evelyne Chesne

  • Izolda Franjkovic

  • Katharina Lechner

  • Martin Kornacker

  • Hearn Jay Cho

Medical Centers

  • Department of Cellular Pathology, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • Melbourne Blood Specialist, East Melbourne, VIC, Australia

  • City of Hope Comprehensive Cancer Center, Monrovia, CA

  • University College London Hospitals NHS Trust, London, United Kingdom

  • Division of Immunology and Rheumatology, Department of Medicine, Stanford University, Stanford, CA

  • University of North Carolina, Chapel Hill, NC

  • The LeBow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Newton, MA

  • Department of Medicine, Duke Univ. Medical Center, Durham, NC

  • Division of Hematology & Medical Oncology, Department of Medicine, Mayo Clinic, Phoenix, AZ

  • Department of Haematology,Prince of Wales Hospital,Sydney,Australien

  • Roche Pharma Research and Early Development, New York, NY

  • Roche Innovation Center Basel, Roche Pharmaceutical Research and Early Development, Basel, Switzerland

  • Roche Innovation Center Penzberg, Roche Pharmaceutical Research and Early Development, Penzberg, Germany

  • MMRF; Icahn School of Medicine at Mount Sinai, Norwalk, CT

Locations

  • United Kingdom

  • United States

  • Australia

  • Switzerland

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Infectious Diseases (ID)

Disease

  • Left ventricular dysfunction

  • Multiple Myeloma

  • Thrombocytopenia

  • Angina

  • Anemia

  • Sepsis

Biomarkers

  • N/A

Drug/Treatment

  • daratumumab Intravenous

Outcome

  • N/A

Study Design

  • Pharmacodynamics

  • Open Label

  • Multicenteric

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • NCT03068351

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved